Application des techniques de thérapie génique aux maladies ostéo-articulaires

Translated title of the contribution: Gene therapy for osteoarticular disorders

J. N. Gouze, Christopher H Evans, Steven C. Ghivizzani, Elvire Gouze

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Osteoarticular disorders are the major cause of disability in Europe and North America. It is estimated that rheumatoid arthritis affects 1 % of the population and that more than two third of people over age 55 develop osteoarthritis. Because there are no satisfactory treatments, gene therapy offers a new therapeutic approach. The delivery of cDNA encoding anti-arthritic proteins to articular cells has shown therapeutic efficacy in numerous animal models in vivo. Through the development and the experimental progresses that have been made for both rheumatoid arthritis and osteoarthritis, this review discusses the different gene therapy strategies available today and the safety issues with which they may be associated. Among the different vectors available today, adeno-associated virus seems the best candidate for a direct in vivo gene delivery approach for the treatment of joint disorders.

Original languageFrench
Pages (from-to)303-309
Number of pages7
JournalMedecine/Sciences
Volume23
Issue number3
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Gene therapy
Genetic Therapy
Viruses
Osteoarthritis
Rheumatoid Arthritis
Animals
Complementary DNA
Genes
Joints
Dependovirus
Therapeutics
North America
Arthritis
Proteins
Animal Models
Safety
Population

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Application des techniques de thérapie génique aux maladies ostéo-articulaires. / Gouze, J. N.; Evans, Christopher H; Ghivizzani, Steven C.; Gouze, Elvire.

In: Medecine/Sciences, Vol. 23, No. 3, 03.2007, p. 303-309.

Research output: Contribution to journalArticle

Gouze, JN, Evans, CH, Ghivizzani, SC & Gouze, E 2007, 'Application des techniques de thérapie génique aux maladies ostéo-articulaires', Medecine/Sciences, vol. 23, no. 3, pp. 303-309.
Gouze, J. N. ; Evans, Christopher H ; Ghivizzani, Steven C. ; Gouze, Elvire. / Application des techniques de thérapie génique aux maladies ostéo-articulaires. In: Medecine/Sciences. 2007 ; Vol. 23, No. 3. pp. 303-309.
@article{4cd13dcc525241479a10bf8f6546601d,
title = "Application des techniques de th{\'e}rapie g{\'e}nique aux maladies ost{\'e}o-articulaires",
abstract = "Osteoarticular disorders are the major cause of disability in Europe and North America. It is estimated that rheumatoid arthritis affects 1 {\%} of the population and that more than two third of people over age 55 develop osteoarthritis. Because there are no satisfactory treatments, gene therapy offers a new therapeutic approach. The delivery of cDNA encoding anti-arthritic proteins to articular cells has shown therapeutic efficacy in numerous animal models in vivo. Through the development and the experimental progresses that have been made for both rheumatoid arthritis and osteoarthritis, this review discusses the different gene therapy strategies available today and the safety issues with which they may be associated. Among the different vectors available today, adeno-associated virus seems the best candidate for a direct in vivo gene delivery approach for the treatment of joint disorders.",
author = "Gouze, {J. N.} and Evans, {Christopher H} and Ghivizzani, {Steven C.} and Elvire Gouze",
year = "2007",
month = "3",
language = "French",
volume = "23",
pages = "303--309",
journal = "M{\'e}decine sciences : M/S",
issn = "0767-0974",
publisher = "Editions EDK",
number = "3",

}

TY - JOUR

T1 - Application des techniques de thérapie génique aux maladies ostéo-articulaires

AU - Gouze, J. N.

AU - Evans, Christopher H

AU - Ghivizzani, Steven C.

AU - Gouze, Elvire

PY - 2007/3

Y1 - 2007/3

N2 - Osteoarticular disorders are the major cause of disability in Europe and North America. It is estimated that rheumatoid arthritis affects 1 % of the population and that more than two third of people over age 55 develop osteoarthritis. Because there are no satisfactory treatments, gene therapy offers a new therapeutic approach. The delivery of cDNA encoding anti-arthritic proteins to articular cells has shown therapeutic efficacy in numerous animal models in vivo. Through the development and the experimental progresses that have been made for both rheumatoid arthritis and osteoarthritis, this review discusses the different gene therapy strategies available today and the safety issues with which they may be associated. Among the different vectors available today, adeno-associated virus seems the best candidate for a direct in vivo gene delivery approach for the treatment of joint disorders.

AB - Osteoarticular disorders are the major cause of disability in Europe and North America. It is estimated that rheumatoid arthritis affects 1 % of the population and that more than two third of people over age 55 develop osteoarthritis. Because there are no satisfactory treatments, gene therapy offers a new therapeutic approach. The delivery of cDNA encoding anti-arthritic proteins to articular cells has shown therapeutic efficacy in numerous animal models in vivo. Through the development and the experimental progresses that have been made for both rheumatoid arthritis and osteoarthritis, this review discusses the different gene therapy strategies available today and the safety issues with which they may be associated. Among the different vectors available today, adeno-associated virus seems the best candidate for a direct in vivo gene delivery approach for the treatment of joint disorders.

UR - http://www.scopus.com/inward/record.url?scp=33947508035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947508035&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 303

EP - 309

JO - Médecine sciences : M/S

JF - Médecine sciences : M/S

SN - 0767-0974

IS - 3

ER -